Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCLI NASDAQ:GRTX NASDAQ:RNAZ NASDAQ:UPC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$0.69+0.1%$0.80$0.46▼$1.92$7.66M0.2217,298 shs4,963 shsGRTXGalera Therapeutics$0.10$0.06$0.02▼$0.15$7.55M2.64237,044 shs25,642 shsRNAZTransCode Therapeutics$7.31-4.5%$8.95$6.08▼$20.99$6.72M1.39177,685 shs1,335 shsUPCUniverse Pharmaceuticals$2.87-4.5%$2.84$2.00▼$11.00$1.60M1.5813,490 shs4,374 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics+3.54%+12.34%-18.39%+20.12%-42.43%GRTXGalera Therapeutics0.00%0.00%+143.90%+354.55%+336.68%RNAZTransCode Therapeutics+1.73%-4.49%-12.07%-14.14%-23.08%UPCUniverse Pharmaceuticals+4.75%-3.91%+2.56%-24.62%+299,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$0.69+0.1%$0.80$0.46▼$1.92$7.66M0.2217,298 shs4,963 shsGRTXGalera Therapeutics$0.10$0.06$0.02▼$0.15$7.55M2.64237,044 shs25,642 shsRNAZTransCode Therapeutics$7.31-4.5%$8.95$6.08▼$20.99$6.72M1.39177,685 shs1,335 shsUPCUniverse Pharmaceuticals$2.87-4.5%$2.84$2.00▼$11.00$1.60M1.5813,490 shs4,374 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics+3.54%+12.34%-18.39%+20.12%-42.43%GRTXGalera Therapeutics0.00%0.00%+143.90%+354.55%+336.68%RNAZTransCode Therapeutics+1.73%-4.49%-12.07%-14.14%-23.08%UPCUniverse Pharmaceuticals+4.75%-3.91%+2.56%-24.62%+299,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics 2.00HoldN/AN/AGRTXGalera Therapeutics 0.00N/AN/AN/ARNAZTransCode Therapeutics 1.00SellN/AN/AUPCUniverse Pharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest UPC, RNAZ, BCLI, and GRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026UPCUniverse Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026RNAZTransCode Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.36) per shareN/AGRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/ARNAZTransCode TherapeuticsN/AN/AN/AN/A$11.27 per shareN/AUPCUniverse Pharmaceuticals$17.86M0.09N/AN/A$99.64 per share0.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$11.62M-$1.90N/AN/AN/AN/AN/A-519.50%5/14/2026 (Estimated)GRTXGalera Therapeutics-$59.08M$0.64N/AN/AN/AN/AN/A-99.34%5/11/2026 (Estimated)RNAZTransCode Therapeutics-$34.66M-$99.36N/AN/AN/AN/A-382.87%-57.10%N/AUPCUniverse Pharmaceuticals-$3.67MN/AN/AN/AN/AN/AN/AN/AN/ALatest UPC, RNAZ, BCLI, and GRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026BCLIBrainstorm Cell Therapeutics-$0.28N/AN/AN/AN/AN/A5/11/2026N/AGRTXGalera Therapeutics-$0.8313N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/ARNAZTransCode TherapeuticsN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.210.21GRTXGalera TherapeuticsN/A9.749.74RNAZTransCode TherapeuticsN/A6.296.29UPCUniverse PharmaceuticalsN/A4.073.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%GRTXGalera Therapeutics50.77%RNAZTransCode TherapeuticsN/AUPCUniverse Pharmaceuticals0.18%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics11.15%GRTXGalera Therapeutics12.90%RNAZTransCode Therapeutics0.01%UPCUniverse Pharmaceuticals57.38%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics4011.04 million8.74 millionOptionableGRTXGalera Therapeutics3075.46 million47.38 millionOptionableRNAZTransCode Therapeutics9920,000917,000Not OptionableUPCUniverse Pharmaceuticals220560,000240,000N/AUPC, RNAZ, BCLI, and GRTX HeadlinesRecent News About These CompaniesUniverse Pharmaceuticals Incorporation Class AApril 29, 2026 | edition.cnn.comUniverse Pharmaceuticals (NASDAQ:UPC) Stock Price Down 2.4% – Time to Sell?April 25, 2026 | defenseworld.netDUniverse Pharmaceuticals Sets February 13 Effective Date for Dual-Class Share StructureFebruary 11, 2026 | tipranks.comUniverse Pharmaceuticals INC Implements Dual-Class Share Structure on Nasdaq Effective February 13, 2026February 11, 2026 | quiverquant.comQUniverse Pharmaceuticals INC Announces Effective Date of Dual-Class Share StructureFebruary 11, 2026 | globenewswire.comUniverse Pharmaceuticals Inc trading resumesOctober 8, 2025 | msn.comUniverse Pharmaceuticals Inc trading halted, volatility trading pauseOctober 8, 2025 | msn.comUniverse Pharmaceuticals Approves Key Resolutions at 2025 AGMSeptember 3, 2025 | msn.comUniverse Pharmaceuticals Reports Decline in Financial Performance Amid Regulatory ChangesAugust 31, 2025 | theglobeandmail.comUniverse Pharmaceuticals Postpones Annual General Meeting Due to Quorum IssueAugust 26, 2025 | msn.comUniverse Pharmaceuticals Inc. (UPC) Stock Price Today - WSJAugust 7, 2025 | wsj.comPharma Playbook: What Practitioners Can Learn from Early UPC LitigationMay 14, 2025 | ipwatchdog.comIUniverse Pharmaceuticals Reports Full Year 2024 EarningsMay 3, 2025 | finance.yahoo.comUniverse Pharmaceuticals INC Announces Share Consolidation Effective March 24, 2025March 20, 2025 | quiverquant.comQUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | gurufocus.comUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | investing.comUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | globenewswire.comUniverse Pharmaceuticals Approves Share Consolidation at Extraordinary MeetingMarch 11, 2025 | tipranks.comUniverse Pharmaceuticals INC Faces Potential Delisting from Nasdaq Due to Delinquent Annual Report FilingFebruary 25, 2025 | quiverquant.comQUniverse Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual ReportFebruary 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesIntel Went From Market Reject to Musk's AI Partner — What Happens Next?By Sam Quirke | April 13, 2026Is Oracle Undervalued as Cloud Growth Accelerates?By Thomas Hughes | April 29, 2026Storm Warning? Rivian's Real Test Is Not a TornadoBy Jeffrey Neal Johnson | April 22, 2026Kinder Morgan’s Cash Flow Drives Upside: Potential Swells in Q1By Thomas Hughes | April 24, 2026Avis Short Squeeze Shocked the Market: Are These 3 Stocks Next?By Dan Schmidt | April 27, 2026UPC, RNAZ, BCLI, and GRTX Company DescriptionsBrainstorm Cell Therapeutics NASDAQ:BCLI$0.69 +0.00 (+0.09%) As of 10:48 AM EasternBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Galera Therapeutics NASDAQ:GRTX$0.10 0.00 (0.00%) As of 10:48 AM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.TransCode Therapeutics NASDAQ:RNAZ$7.31 -0.34 (-4.50%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.Universe Pharmaceuticals NASDAQ:UPC$2.86 -0.14 (-4.50%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
